Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy does not appear to reduce the effectiveness of HRT the way it can with some oral contraceptives. For most women taking hormone replacement therapy, semaglutide is not expected to interfere with their hormones — but the picture depends on the form of HRT you use, and that distinction is worth understanding clearly. As a prescription-only medicine, Wegovy must be assessed alongside your full medical history before a prescriber can determine whether it is suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A number of women arrive at consultations having read that GLP-1 medicines are incompatible with HRT, or that they must stop hormone replacement therapy before starting Wegovy. That is not what the evidence or official guidance says. The concern is more specific than that, and getting the detail right matters, because unnecessary worry about an interaction that doesn't apply to your form of HRT could mean missing out on treatment that benefits both your weight and your long-term health.
Semaglutide, the active ingredient in Wegovy, slows the rate at which the stomach empties food and fluid into the small intestine. That is partly how it reduces appetite. The side effect of that mechanism, though, is that oral medicines taken alongside food can be absorbed more slowly or less completely than usual. For most HRT preparations, this simply does not apply, because most women in the UK now use HRT that never goes near the gut at all.
The NHS England guidance on weight-management injections, which covers the precautionary advice for this class of medicines, focuses on oral HRT as the preparation worth discussing with a doctor. If you are already on transdermal HRT, this particular interaction is not considered a concern. That is the fact the 'don't mix' headline misses.
Transdermal HRT, meaning patches worn on the skin, gels rubbed in daily, or sprays applied to the arm, delivers oestrogen directly into the bloodstream through the skin. There is no journey through the stomach. Slowed gastric emptying cannot influence something that never passed through the gut, so the absorption concern does not arise. The same is true of vaginal oestrogen preparations used locally for urogenital symptoms.
Oral HRT tablets are the preparation that warrants care. Because they are swallowed and absorbed through the gut wall, any slowing of gastric emptying could, in theory, reduce or delay how much hormone reaches the bloodstream. This is not yet quantified in robust clinical trial data specifically for semaglutide, but the precautionary advice from NHS England is clear: women taking oral HRT alongside GLP-1 medicines should discuss switching to a transdermal preparation with their prescribing doctor.
It is worth noting that the NHS England guidance cited here was written with tirzepatide (Mounjaro) most explicitly in mind, and the gastric-emptying mechanism is shared by semaglutide. Anyone reading about semaglutide in detail will find the mechanism described the same way across sources. Prescribers treat the caution as applicable to both medicines.
The practical step is straightforward. Before starting any GLP-1 weight-loss treatment, tell your prescriber exactly which HRT preparation you use, the name, the dose, and the form. If you are already on a patch, gel or spray, the conversation is likely short. If you take an oral tablet, your prescriber may suggest discussing a switch to a transdermal option with your GP before treatment begins, or may make a clinical judgement based on your full picture.
This is not an automatic barrier to treatment. It is a normal part of the clinical review that should happen with any prescription medicine. At nume, a GPhC-registered Independent Prescriber reads every consultation personally and will flag exactly this kind of interaction if it is relevant to you. The effect on menstrual cycles and interaction with the coil are separate questions that our clinical team fields regularly too, the answers are different in each case.
Women considering Wegovy who want to understand the full cost and process before committing can find a straightforward breakdown on the Wegovy cost in the UK page. And if you are curious about other unexpected effects semaglutide can have, the change in food taste many people notice is worth reading about before you start.
When you are ready to talk to a prescriber about your own situation, the right starting point is a free clinical consultation. Your prescriber will look at your HRT, your other medicines, your medical history, and your weight-loss goals together, and give you a clear answer specific to you, not a generalised one. Start your free consultation with the nume clinical team whenever you are ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.